• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tao Synergies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/19/25 4:23:07 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    false 0001571934 0001571934 2025-12-18 2025-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    Of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 18, 2025

     

     

     

    TAO Synergies Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40458   48-1585656
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    1185 Avenue of the Americas, 3rd Floor
    New York, New York 10036
    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (973) 242-0005

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which
    registered
    Common Stock, $0.0001 par value per share   TAOX   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company. x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e) At the Annual Meeting (as defined below) of TAO Synergies Inc. (the “Company”), stockholders approved an amendment and restatement of the Company’s 2020 Equity Incentive Plan (as amended and restated, the “Amended and Restated Equity Incentive Plan”) to increase the number of shares of common stock (“Common Stock”) reserved for issuance thereunder by 500,000 shares to 3,175,000 shares.

     

    The foregoing description of the Amended and Restated Equity Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Equity Incentive Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K (the “Current Report”) and incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On December 18, 2025, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the holders of 3,318,341 shares of the Company’s Common Stock, or approximately 43.18% of the Company’s outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, the Company’s stockholders considered five proposals, which are described briefly below and in more detail in the proxy statement. The final voting results for each proposal are set forth below.

     

    Proposal 1 – Election of Directors

     

    The Company’s stockholders voted to elect one director, Bruce T. Bernstein, to hold office until the 2028 annual meeting of stockholders, and until his successor is elected and qualified, by the following votes:

     

    Nominee   Shares Voted For   Shares Voted Against   Abstentions
    Bruce T. Bernstein   1,040,943   74,437   12,198

     

    Proposal 2 - Approval of the Issuance of Common Stock Underlying Shares of Convertible Preferred Stock and Warrants

     

    The Company’s stockholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of (a) that certain Securities Purchase Agreement, dated October 13, 2025, by and among the Company and the investors named therein and (b) that certain engagement letter by and among the Company and GP Nurmenkari Inc. as placement agent, in an amount equal to or in excess of 20% of the Company’s Common Stock outstanding before the issuance of such convertible preferred stock and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants), by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    504,481   78,798   2,109

     

    Proposal 3 – Approval of Amendment to Equity Incentive Plan

     

    The Company’s stockholders voted to approve a proposed amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares available for the grant of awards by 500,000 shares, by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    994,315   110,637   22,626

     

     

     

     

    Proposal 4 – Ratification of Selection of Independent Registered Public Accounting Firm

     

    The ratification of the appointment of Stephano Slack LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    3,241,023   22,536   54,782

     

    Proposal 5 - Approval of Adjournment

     

    The Company’s stockholders voted to approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to adopt either of Proposal #2 or Proposal #3 or to establish a quorum, by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    3,210,518   150,935   46,883

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Amended and Restated TAO Synergies Inc. 2020 Equity Incentive Plan
    104   Cover Page Interactive Data File (embedded within the Inline XBRL Document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant hass duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      TAO SYNERGIES INC.

     

    Date: December 19, 2025 By: /s/ Robert Weinstein
      Name: Robert Weinstein
      Title: Chief Financial Officer

     

     

    Get the next $TAOX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

    November 18 at 12:15 p.m. ET—Bittensor expert James Altucher and Yuma CRO Evan Malanga dive deep into TAO, decentralized AI, and network outlook as TAO halving approaches TAO Synergies is the largest publicly traded holder of Bittensor's native TAO token, first public company to invest in blockchain subnets NEW YORK, Nov. 18, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that it will partner with Yuma to participate in a Yuma Asset Management Investor Spotlight, an X Livestream event today, Tuesday

    11/18/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

    Seeks to optimize returns for shareholders while fostering evolution of Bittensor's decentralized machine intelligence marketplace NEW YORK, Nov. 4, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced an initial $750,000 investment in Yuma Asset Management's Bittensor Subnet Funds, enhancing the Company's exposure to subnets in the Bittensor ecosystem. These positions demonstrate TAO Synergies' commitment to decentralized AI, the Bittensor / TAO crypto token, and subnet tokens that will ultimately drive t

    11/4/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that through acquisition and staking, the Company's total TAO holdings have increased to 54,058 tokens. This further solidifies TAO Synergies' position as the largest publicly traded pure-play holder of Bittensor (TAO), the groundbreaking protocol powering decentralized AI innovation. TAO Synergies continues to execute on its mission to democratize access to decentralized AI for retail and institutional investors alike, while capturin

    10/20/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weinstein Robert covered exercise/tax liability with 4,000 shares and was granted 10,000 shares, increasing direct ownership by 57% to 16,574 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:14:09 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Singer William S. was granted 15,000 shares and covered exercise/tax liability with 6,000 shares, increasing direct ownership by 85% to 19,566 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:13:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Silverman Joshua was granted 100,000 shares and covered exercise/tax liability with 40,000 shares, increasing direct ownership by 225% to 86,681 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:12:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    SEC Filings

    View All

    Tao Synergies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TAO Synergies Inc. (0001571934) (Filer)

    12/19/25 4:23:07 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Tao Synergies Inc.

    DEF 14A - TAO Synergies Inc. (0001571934) (Filer)

    11/17/25 4:50:47 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tao Synergies Inc.

    10-Q - TAO Synergies Inc. (0001571934) (Filer)

    11/14/25 4:18:43 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care